HRT Financial’s Adverum Biotechnologies ADVM Stock Holding History

HRT Financial’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,627	Closed	-$65K	–	2787
2025 Q2	$65K	Buy	+30,627	New	+$85.7K	﹤0.01%	2271
2023 Q4	–	Sell	-2,510	Closed	-$37K	–	2241
2023 Q3	$37K	Buy	+2,510	New	+$45.1K	﹤0.01%	2022
2022 Q1	–	Sell	-21,242	Closed	-$373K	–	3016
2021 Q4	$373K	Sell	21,242 -63,555	-75%	-$1.27M	﹤0.01%	2115
2021 Q3	$1.84M	Buy	+84,797	New	+$2.16M	0.01%	799
2021 Q1	–	Sell	-7,290	Closed	-$790K	–	2635
2020 Q4	$790K	Buy	+7,290	New	+$902K	0.02%	792
2020 Q1	–	Sell	-2,579	Closed	-$297K	–	727
2019 Q4	$297K	Sell	2,579 -504	-16%	-$44.4K	0.01%	750
2019 Q3	$168K	Buy	+3,083	New	+$347K	0.01%	1187

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

HRT Financial's ADVM Position: Q3 2025 in Review

HRT Financial sold out of Adverum Biotechnologies (ADVM) in Q3 2025, closing a stake of 30,627 shares — an estimated $65K sold.

HRT Financial first reported a position in ADVM in Q3 2019 and held it in 7 quarters. The position peaked at $1.84M in Q3 2021. 50 funds tracked by Wall St. Rank hold ADVM as of Q3 2025.

HRT Financial reported no remaining Adverum Biotechnologies position as of Q3 2025 after selling out during the quarter.
HRT Financial sold 30,627 Adverum Biotechnologies shares in Q3 2025, an estimated $65K.
HRT Financial first reported a position in Adverum Biotechnologies in Q3 2019 and held it in 7 quarters.
HRT Financial's Adverum Biotechnologies position peaked at $1.84M in Q3 2021.
50 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.